BioWorld

April 29, 2010

For Now, MS Twin Study Yields More Questions, Not Answers

Lycera's Progress Triggers $11M in Second Part of Series A Round

Other News To Note

Stock Movers

Clinic Roundup

Huntington's Drug Snagged on Statistics; Another Trial Needed?

Shares of NeuroSearch A/S sank 30 percent when it turned out the firm's positive Phase III Huntington's disease trial was not quite so positive after all. (BioWorld Today) Read More

More Bush-Era Stem Cell Lines OK'd by NIH for Federal Funds

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...